Top

Published in:

01-01-2008 | Gastrointestinal Oncology

Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer resection: a meta-analysis

Authors: Sushil Rekhraj, MSc, MRCS, Omer Aziz, BSc, MRCS, Shirish Prabhudesai, MS, MRCS, Emmanouil Zacharakis, MD, PhD, Franziska Mohr, MD, Thanos Athanasiou, MD, PhD, FETCS, Ara Darzi, MD, FMedSci, HonFREng, KBE, Paul Ziprin, MD, FRCS

Published in: Annals of Surgical Oncology | Issue 1/2008

Abstract

Background

Accurate staging of colorectal cancer is important for predicting prognosis and guiding treatment. This study uses meta-analysis to investigate if the pre- or post-resection detection of intraperitoneal free cancer cells can predict recurrence in patients undergoing curative colorectal cancer surgery.

Methods

A literature search was performed on all studies between January 1990 and July 2007 comparing the detection of intraperitoneal free cancer cells either pre- or post-resection with prognosis in colorectal cancer. The following prognostic outcomes were meta-analyzed: overall recurrence rate and local recurrence rate. A random-effect model was used and heterogeneity was assessed.

Results

Nine studies reporting on a total of 1182 subjects matched the selection criteria. Free cancer cells were detected prior to tumor resection in 125/822 (15.2%) of patients and following resection in 64/533 (12%) of patients. Preresection, the absence of tumor cells was associated with a lower overall recurrence (25.2%) compared to the presence of tumor cells [46.4%, odds ratio (OR) = 0.41, confidence interval (CI) 0.19–0.88]; as well as a significantly lower local recurrence (12.2% versus 21.1%, OR = 0.42, CI 0.21–0.82). Postresection, the absence of tumor cells also resulted in significantly lower overall recurrence (17.3%) when compared to the presence of tumor cells (52.6%, OR = 0.07, CI 0.03–0.18).

Conclusions

The detection of intraperitoneal free cancer cells is associated with higher recurrence and poorer prognosis. Use of these techniques can identify patients at higher recurrence risk. This could be particularly valuable in stage II disease to identify patients who may benefit from adjuvant chemotherapy.

Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108PubMedCrossRef

Dukes CE. The classification of cancer of the rectum. J Pathol Bacteriol 1932;35:323–32CrossRef

Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846–52PubMedCrossRef

Hutter RV. At last–worldwide agreement on the staging of cancer. Arch Surg 1987;122:1235–9PubMed

Jass JR, O’Brien MJ, Riddell RH, et al. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Hum Pathol 2007

Merkel S, Mansmann U, Papadopoulos T, et al. The prognostic inhomogeneity of colorectal carcinomas Stage III: a proposal for subdivision of Stage III. Cancer 2001;92:2754–9PubMedCrossRef

Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg 2002;236:416–21PubMedCrossRef

Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223–8PubMedCrossRef

Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583–96PubMedCrossRef

10.

Michelassi F, Vannucci L, Ayala JJ, et al. Local recurrence after curative resection of colorectal adenocarcinoma. Surgery 1990;108:787–92PubMed

11.

Hansen E, Wolff N, Knuechel R, et al. Tumor cells in blood shed from the surgical field. Arch Surg 1995;130:387–93PubMed

12.

Feezor RJ, Copeland EM, III, Hochwald SN. Significance of micrometastases in colorectal cancer. Ann Surg Oncol 2002;9:944–53PubMedCrossRef

13.

Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465–72PubMedCrossRef

14.

Umpleby HC, Fermor B, Symes MO, et al. Viability of exfoliated colorectal carcinoma cells. Br J Surg 1984;71:659–63PubMedCrossRef

15.

Fermor B, Umpleby HC, Lever JV, et al. Proliferative and metastatic potential of exfoliated colorectal cancer cells. J Natl Cancer Inst 1986;76:347–9PubMed

16.

Skipper D, Cooper AJ, Marston JE, et al. Exfoliated cells and in vitro growth in colorectal cancer. Br J Surg 1987;74:1049–52PubMedCrossRef

17.

Uras C, Altinkaya E, Yardimci H, et al. Peritoneal cytology in the determination of free tumour cells within the abdomen in colon cancer. Surg Oncol 1996;5:259–63PubMedCrossRef

18.

Leather AJ, Gallegos NC, Kocjan G, et al. Detection and enumeration of circulating tumour cells in colorectal cancer. Br J Surg 1993;80:777–80PubMedCrossRef

19.

Aoki S, Takagi Y, Hayakawa M, et al. Detection of peritoneal micrometastases by reverse transcriptase-polymerase chain reaction targeting carcinoembryonic antigen and cytokeratin 20 in colon cancer patients. J Exp Clin Cancer Res 2002;21:555–62PubMed

20.

Ojima H, Sasaki S, Fujisawa T, et al. Utility of serosal stamp cytology as an indicator for high-risk peritoneal metastasis in colorectal cancer surgery. Hepatogastroenterology 2003;50:87–90PubMed

21.

Leather AJ, Kocjan G, Savage F, et al. Detection of free malignant cells in the peritoneal cavity before and after resection of colorectal cancer. Dis Colon Rectum 1994;37:814–9PubMedCrossRef

22.

Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005;12:347–53PubMedCrossRef

23.

Ribeiro U, Jr., Safatle-Ribeiro AV, Zilberstein B, et al. Does the intraoperative peritoneal lavage cytology add prognostic information in patients with potentially curative gastric resection? J Gastrointest Surg 2006;10:170–6, discussionPubMedCrossRef

24.

Rosenberg R, Nekarda H, Bauer P, et al. Free peritoneal tumour cells are an independent prognostic factor in curatively resected stage IB gastric carcinoma. Br J Surg 2006;93:325–31PubMedCrossRef

25.

Benedet JL, Bender H, Jones H, III, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209–62PubMedCrossRef

26.

Kienle P, Koch M. Minimal residual disease in gastrointestinal cancer. Semin Surg Oncol 2001;20:282–93PubMedCrossRef

27.

Clarke. Cochrane reviewer’s handbook 4.1.3. Oxford, UK: The Cochrane Library, 2001

28.

Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Onkologie 2000;23:597–602PubMedCrossRef

29.

Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34PubMed

30.

Egger M, Smith GD. Misleading meta-analysis. BMJ 1995;311:753–4PubMed

31.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88PubMedCrossRef

32.

Gozalan U, Yasti AC, Yuksek YN, et al. Peritoneal cytology in colorectal cancer: incidence and prognostic value. Am J Surg 2007;193:672–5PubMedCrossRef

33.

Kanellos I, Zacharakis E, Kanellos D, et al. Prognostic significance of CEA levels and positive cytology in peritoneal washings in patients with colorectal cancer. Colorectal Dis 2006;8:436–40PubMedCrossRef

34.

Lloyd JM, McIver CM, Stephenson SA, et al. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Clin Cancer Res 2006;12:417–23PubMedCrossRef

35.

Baskaranathan S, Philips J, McCredden P, et al. Free colorectal cancer cells on the peritoneal surface: correlation with pathologic variables and survival. Dis Colon Rectum 2004;47:2076–9PubMedCrossRef

36.

Kanellos I, Demetriades H, Zintzaras E, et al. Incidence and prognostic value of positive peritoneal cytology in colorectal cancer. Dis Colon Rectum 2003;46:535–9PubMedCrossRef

37.

Yamamoto S, Akasu T, Fujita S, et al. Long-term prognostic value of conventional peritoneal cytology after curative resection for colorectal carcinoma. Jpn J Clin Oncol 2003;33:33–7PubMedCrossRef

38.

Bosch B, Guller U, Schnider A, et al. Perioperative detection of disseminated tumour cells is an independent prognostic factor in patients with colorectal cancer. Br J Surg 2003;90:882–8PubMedCrossRef

39.

Guller U, Zajac P, Schnider A, et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002;236:768–75PubMedCrossRef

40.

Vogel I, Francksen H, Soeth E, et al. The carcinoembryonic antigen and its prognostic impact on immunocytologically detected intraperitoneal colorectal cancer cells. Am J Surg 2001;181:188–93PubMedCrossRef

41.

Vogel P, Ruschoff J, Kummel S, et al. Prognostic value of microscopic peritoneal dissemination: comparison between colon and gastric cancer. Dis Colon Rectum 2000;43:92–100PubMedCrossRef

42.

Wind P, Norklinger B, Roger V, et al. Long-term prognostic value of positive peritoneal washing in colon cancer. Scand J Gastroenterol 1999;34:606–10PubMedCrossRef

43.

Hase K, Ueno H, Kuranaga N, et al. Intraperitoneal exfoliated cancer cells in patients with colorectal cancer. Dis Colon Rectum 1998;41:1134–40PubMedCrossRef

44.

Schott A, Vogel I, Krueger U, et al. Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg 1998;227:372–9PubMedCrossRef

45.

Broll R, Lembcke K, Stock C, et al. Tumor cell dissemination in bone marrow and peritoneal cavity. An immunocytochemical study of patients with stomach or colorectal carcinoma. Langenbecks Arch Chir 1996;381:51–8PubMedCrossRef

46.

Ambrose NS, MacDonald F, Young J, et al. Monoclonal antibody and cytological detection of free malignant cells in the peritoneal cavity during resection of colorectal cancer–can monoclonal antibodies do better? Eur J Surg Oncol 1989;15:99–102PubMed

47.

Vogel P, Ruschoff J, Kummel S, et al. Immunocytology improves prognostic impact of peritoneal tumour cell detection compared to conventional cytology in gastric cancer. Eur J Surg Oncol 1999;25:515–9PubMedCrossRef

48.

To EM, Chan WY, Chow C, et al. Gastric cancer cell detection in peritoneal washing: cytology versus RT-PCR for CEA transcripts. Diagn Mol Pathol 2003;12:88–95PubMedCrossRef

49.

Lindemann F, Schlimok G, Dirschedl P, et al. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340:685–9PubMedCrossRef

50.

Eisenberg B, Decosse JJ, Harford F, et al. Carcinoma of the colon and rectum: the natural history reviewed in 1704 patients. Cancer 1982;49:1131–4PubMedCrossRef

51.

Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–7PubMedCrossRef

52.

Benson AB, III, Choti MA, Cohen AM, et al. NCCN Practice Guidelines for Colorectal Cancer. Oncology 2000;14:203–12PubMed

53.

Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 2004;22:3395–407PubMedCrossRef

54.

Benson AB, III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408–19PubMedCrossRef

55.

Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011–9PubMedCrossRef

56.

Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum 1991;34:723–7PubMedCrossRef

57.

Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43(Suppl):S15–S25PubMedCrossRef

Title: Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer resection: a meta-analysis
Authors: Sushil Rekhraj, MSc, MRCS
Omer Aziz, BSc, MRCS
Shirish Prabhudesai, MS, MRCS
Emmanouil Zacharakis, MD, PhD
Franziska Mohr, MD
Thanos Athanasiou, MD, PhD, FETCS
Ara Darzi, MD, FMedSci, HonFREng, KBE
Paul Ziprin, MD, FRCS
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9591-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Can intra-operative intraperitoneal free cancer cell detection techniques identify patients at higher recurrence risk following curative colorectal cancer resection: a meta-analysis

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2008

‘Telangiectatic’ Transformation in Soft Tissue Sarcomas. A Clinicopathology Analysis of an Aggressive Feature of High-grade Sarcomas

Preservation of the Internal Jugular Vein in the Radical Treatment of Node-Positive Neck—Is It Safe?

Improved Long-Term Outcome of Surgery for Advanced Colorectal Liver Metastases: Reasons and Implications for Management on the Basis of a Severity Score

Prognostic Factors for Primary GIST: Prime Time for Personalized Therapy?

Predictors of Complications and Outcomes of External Hemipelvectomy Wounds: Account of 160 Consecutive Cases

Does Lymphadenectomy Improve Survival of Patients with Solid Tumors?